Genomics

Life sciences giant QIAGEN defies economic headwinds with strong 2025 results, signaling aggressive growth in single-cell analysis and bioinformatics.

Death rates fall, but a new report reveals rising incidence and stark inequities. Can new drugs and AI reshape the future for all patients?

JScreen, Manischewitz, and advocate Gila Pfeffer offer low-cost cancer and carrier genetic tests in NYC, transforming community health access.

After selling its proteomics arm to Illumina for $350M+, Standard BioTools is flush with cash but faces a pivotal moment to fix its core business.

Veteran leader Emma Rooth takes charge at PCCA UK, bringing a track record of transformation to the booming personalized medicine market.

Neurocrine Biosciences begins a Phase 2 trial for a new tardive dyskinesia drug, aiming to build on its market dominance and offer new hope for patients.

PulseSight's first-in-class gene therapy for dry AMD completes its Phase I trial, offering a novel approach to a leading cause of vision loss.

A new, self-administered RNA therapy for hereditary angioedema gains EU approval, promising fewer attacks and greater freedom for thousands of patients.

A bipartisan House bill aims to standardize Medicaid coverage for genetic sequencing, offering hope to families facing long waits for a diagnosis.

Equinox's new EQX ARC program partners with Oura and Function to offer hyper-personalized, data-driven training for women across all life stages.

Jennifer Erickson, a mentee of the retiring CEO, returns to lead Arizona's top lab, signaling a new era of innovation amid industry-wide shifts.

Genomics giant Illumina launches a vast biological dataset with pharma partners, aiming to train AI and revolutionize how we find new medicines.

Cosmetics brand Sorevna is diving into the crowded bath and body sector, promising a revolutionary launch. But can its science-first approach succeed?

ConcertAI and Foundation Medicine unite to create a huge dataset of 500k patients, using AI to accelerate the hunt for new life-saving cancer drugs.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

Promising Phase 2 data shows a new DNA immunotherapy for advanced melanoma, delivered via a needle-free jet injector, significantly improves patient outcomes.

A new partnership brings revolutionary 3D genome mapping from the lab to the clinic, offering new hope for patients with hard-to-treat cancers.

Pharma giant Bayer partners with biotech innovator Soufflé to develop a groundbreaking siRNA therapy, aiming to deliver genetic medicine directly to the heart.

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

Azitra will present its novel AI-driven skin therapies for rare diseases at Biotech Showcase, seeking crucial funding and partnerships to advance its pipeline.